Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor

被引:64
|
作者
Schmidt, Karsten [1 ]
Prakash, Thazha P. [1 ]
Donner, Aaron J. [1 ]
Kinberger, Garth A. [1 ]
Gaus, Hans J. [1 ]
Low, Audrey [1 ]
Ostergaard, Michael E. [1 ]
Bell, Melanie [1 ]
Swayze, Eric E. [1 ]
Seth, Punit P. [1 ]
机构
[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA
关键词
TARGETED DELIVERY; MEDIATED ENDOCYTOSIS; HIGH-AFFINITY; MICE LACKING; IN-VIVO; HEPATOCYTES; SUBUNIT; LIGAND; LIVER; OLIGODEOXYNUCLEOTIDES;
D O I
10.1093/nar/gkx060
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs similar to 30-fold in the clinic (1). In order to fully characterize the effect of GalNAc valency, oligonucleotide length, flexibility and chemical composition on ASGR binding, we tested and validated a fluorescence polarization competition binding assay. The ASGR binding, and in vitro and in vivo activities of 1, 2 and 3 GalNAc conjugated single stranded and duplexed ASOs were studied. Two and three GalNAc conjugated single stranded ASOs bind the ASGR with the strongest affinity and display optimal in vitro and in vivo activities. 1 GalNAc conjugated ASOs showed 10-fold reduced ASGR binding affinity relative to three GalNAc ASOs but only 2-fold reduced activity in mice. An unexpected observation was that the ASGR also appears to play a role in the uptake of unconjugated phosphorothioate modified ASOs in the liver as evidenced by the loss of activity of GalNAc conjugated and unconjugated ASOs in ASGR knockout mice. Our results provide insights into how backbone charge and chemical composition assist in the binding and internalization of highly polar anionic single stranded oligonucleotides into cells and tissues.
引用
收藏
页码:2294 / 2306
页数:13
相关论文
共 28 条
  • [1] Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
    Tanowitz, Michael
    Hettrick, Lisa
    Revenko, Alexey
    Kinberger, Garth A.
    Prakash, Thazha P.
    Seth, Punit P.
    NUCLEIC ACIDS RESEARCH, 2017, 45 (21) : 12388 - 12400
  • [2] Effect of benzalkonium chloride on percutaneous absorption of antisense phosphorothioate oligonucleotides
    Lee, YM
    Lee, SH
    Ko, GI
    Kim, JB
    Sohn, DH
    ARCHIVES OF PHARMACAL RESEARCH, 1996, 19 (06) : 435 - 440
  • [3] Mixed-backbone oligonucleotides containing phosphorothioate and methylphosphonate linkages as second generation antisense oligonucleotide
    Agrawal, S
    Jiang, ZW
    Zhao, QY
    Shaw, D
    Sun, D
    Saxinger, C
    NUCLEOSIDES & NUCLEOTIDES, 1997, 16 (7-9): : 927 - 936
  • [4] Antisense inhibitory effect:: A comparison between 3′-partial and full phosphorothioate antisense oligonucleotides
    Galderisi, U
    Di Bernardo, G
    Melone, MAB
    Galano, G
    Cascino, A
    Giordano, A
    Cipollaro, M
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1999, 74 (01) : 31 - 37
  • [5] Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
    Bailey, Jeffrey K.
    Shen, Wen
    Liang, Xue-hai
    Crooke, Stanley T.
    NUCLEIC ACIDS RESEARCH, 2017, 45 (18) : 10649 - 10671
  • [6] Antisense phosphorothioate oligonucleotides targeted to the human chemokine receptor CXCR4
    Kusunoki, A
    Miyano-Kurosaki, N
    Kimura, T
    Takai, K
    Yamamoto, N
    Gushima, H
    Takaku, H
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2000, 19 (10-12): : 1709 - 1719
  • [7] Novel backbone modified antisense oligonucleotides with improved potency effectively inactivate oncogenic miRNA-21 comparing to phosphorothioate oligonucleotides
    Miroshnichenko, S.
    Patutina, O.
    Burakova, E.
    Chelobanov, B.
    Fokina, A.
    Stetsenko, D.
    Vlassov, V.
    Zenkova, M.
    FEBS OPEN BIO, 2018, 8 : 107 - 107
  • [8] Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver
    Miller, Colton M.
    Tanowitz, Michael
    Donner, Aaron J.
    Prakash, Thazha P.
    Swayze, Eric E.
    Harris, Edward N.
    Seth, Punit P.
    NUCLEIC ACID THERAPEUTICS, 2018, 28 (03) : 119 - 127
  • [9] Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects
    Zhou, WQ
    Agrawal, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) : 3269 - 3274
  • [10] Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′-MOE and Phosphorothioate Modified Antisense Oligonucleotides
    Wang, Yanfeng
    Diep, John K.
    Yu, Rosie Z.
    Hurh, Eunju
    Karwatowska-Prokopczuk, Ewa
    Schneider, Eugene
    Henry, Scott
    Bhanot, Sanjay
    Geary, Richard S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (01): : 21 - 28